Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
SVRA 
Savara Inc (SVRA)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: SVRA (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
8 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $8.36
1 Year Target Price $8.36
| 4 | Strong Buy |
| 2 | Buy |
| 2 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -15.52% | Avg. Invested days 36 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 568.63M USD | Price to earnings Ratio - | 1Y Target Price 8.36 |
Price to earnings Ratio - | 1Y Target Price 8.36 | ||
Volume (30-day avg) 8 | Beta 0.4 | 52 Weeks Range 1.89 - 4.70 | Updated Date 08/29/2025 |
52 Weeks Range 1.89 - 4.70 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.51 |
Earnings Date
Report Date 2025-08-13 | When - | Estimate -0.12 | Actual -0.14 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -48.04% | Return on Equity (TTM) -99.3% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 448476734 | Price to Sales(TTM) 131146 |
Enterprise Value 448476734 | Price to Sales(TTM) 131146 | ||
Enterprise Value to Revenue 11.91 | Enterprise Value to EBITDA -4.76 | Shares Outstanding 172836992 | Shares Floating 86677904 |
Shares Outstanding 172836992 | Shares Floating 86677904 | ||
Percent Insiders 5.38 | Percent Institutions 100.02 |
Upturn AI SWOT
Savara Inc
Company Overview
History and Background
Savara Inc., founded in 2011, is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. They focus on development and commercialization of innovative therapies for the treatment of orphan lung diseases.
Core Business Areas
- Molgradex: Molgradex (GM-CSF) is an inhaled formulation of granulocyte-macrophage colony-stimulating factor being developed for autoimmune pulmonary alveolar proteinosis (aPAP).
Leadership and Structure
Matt Pauls is the Chief Executive Officer. The company operates with a typical biopharmaceutical organizational structure, including research & development, clinical operations, commercial planning, and finance.
Top Products and Market Share
Key Offerings
- Molgradex: Molgradex is Savara's lead investigational product for aPAP. It competes with whole lung lavage (WLL) the current standard of care. They are pursuing regulatory approvals globally, including the US and Europe.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and research-intensive, with a focus on developing and commercializing new therapies. It's heavily regulated and subject to significant clinical and regulatory risks.
Positioning
Savara Inc. is positioned as a specialized biopharmaceutical company focusing on orphan lung diseases, specifically aPAP, a niche area with unmet medical need. The advantage includes the market exclusivity if Molgradex receives approval.
Total Addressable Market (TAM)
The aPAP market is estimated at several hundred million dollars globally. Savara is positioned to capture a significant share of this market if Molgradex is approved. Exact market size estimates vary depending on pricing and penetration.
Upturn SWOT Analysis
Strengths
- Focus on a rare disease with unmet need
- Potential for market exclusivity with Molgradex
- Experienced management team in respiratory therapeutics
- Advanced clinical development stage for lead asset
Weaknesses
- Single product focus creates high risk
- Reliance on successful clinical trial outcomes and regulatory approvals
- Limited commercial infrastructure
- Dependence on capital markets for funding
Opportunities
- Expansion into other orphan lung diseases
- Partnerships with larger pharmaceutical companies
- Potential for priority review and orphan drug designation
- Geographic expansion
Threats
- Clinical trial failures
- Regulatory delays or rejection
- Competition from other therapies
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- JAZZ
- GBT
Competitive Landscape
Savara faces competition primarily from the current standard of care, whole lung lavage (WLL). The competitive advantage of Molgradex is its potential to be a less invasive and more convenient treatment option.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been limited as the company is pre-commercial. Stock price has varied significantly based on clinical trial results.
Future Projections: Future growth is dependent on the successful development and commercialization of Molgradex. Analyst estimates vary widely based on assumptions about regulatory approval and market penetration.
Recent Initiatives: Recent initiatives include ongoing clinical trials for Molgradex, regulatory submissions in key markets, and pre-commercialization planning.
Summary
Savara is a high-risk, high-reward biopharmaceutical company focused on a rare lung disease. Success hinges on Molgradex gaining regulatory approval and acceptance. The company needs to effectively manage its cash and capital to navigate clinical and regulatory milestones, but there is great growth potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Savara Inc. Investor Relations
- SEC Filings
- Industry Reports
- Analyst Reports
Disclaimers:
The information provided is for informational purposes only and should not be considered investment advice. Financial data is based on publicly available information and may not be completely accurate. Investment decisions should be based on individual research and consultation with a financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Savara Inc
Exchange NASDAQ | Headquaters Langhorne, PA, United States | ||
IPO Launch date 2017-06-01 | Chairman & CEO Mr. Matthew Pauls J.D., M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 59 | Website https://www.savarapharma.com |
Full time employees 59 | Website https://www.savarapharma.com | ||
Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. The company's lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase 3 development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company was founded in 2007 and is headquartered in Langhorne, Pennsylvania.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.